Brain Cancer Clinical Trial
Official title:
Relationship Among Fatigue, Symptoms, Melatonin and Sleep in PBT Patients Undergoing Radiation Therapy
This goal of this research study is to learn more about fatigue, sleep quality, and other
symptoms in patients with primary brain tumors who are being treated with radiation therapy.
Objectives:
PRIMARY OBJECTIVE:
1. The primary objective of this study is to provide preliminary data describing the
severity and change over time in fatigue using the Brief Fatigue Inventory (BFI) during
radiation therapy for patients with primary gliomas.
SECONDARY OBJECTIVES:
1. To evaluate longitudinal changes in the severity of symptoms and the mean symptom
burden as measured by the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
and mood using the Profile of Mood States (POMS) during radiation therapy.
2. To assess alterations in circadian rhythms using actigraphy during radiation therapy
and the association with sleep quality tools - Pittsburgh Sleep Quality Index (PSQI)
and the Epworth Sleepiness Scale(ESS), and the severity of BFI and MDASI-BT scores over
time.
3. To explore the association between the levels of salivary hormones (melatonin and
cortisol) and the occurrence of fatigue and symptom burden.
Questionnaires:
If you decide to take part in this study, before starting radiation therapy, weekly during
radiation therapy, and again 3-4 weeks and 6-8 weeks after completing radiation therapy, you
will complete 4 questionnaires. Three (3) of the questionnaires will be completed during a
study visit, and the last 1 will be completed at home the next time you come into the
clinic. You will return the questionnaire completed at home to the study doctor at a study
visit. The questionnaires will ask questions about fatigue, any symptoms you may have, and
your sleeping habits. It should take about 30 minutes total to complete all of the
questionnaires each time.
Sleep Diary:
You will complete a sleep diary. The sleep diary will be provided to you before starting
radiation therapy. You will record information in it about your sleep habits, caffeinated
beverages and drugs you may take, the quality of your sleep, and how you feel when you wake
up. You will complete the sleep diary during the 48 hours that you are wearing the
actigraphy watch. You will bring the sleep diary to the clinic every week for the study
doctor to review.
Actigraphy Watch:
You will wear an actigraphy watch on your wrist for 48 hours before starting radiation
therapy, for 48 hours each week during radiation therapy, and again for 48 hours 3-4 weeks
and 6-8 weeks after completing radiation therapy. The actigraphy watch will measure your
activity during the day and night. You will bring the actigraphy watch to the clinic every
week for the study doctor to review.
Saliva Collection:
You will collect a saliva sample four times during the day before starting radiation
therapy, one time during the third and last week of radiation therapy, and again 3-4 weeks
and 6-8 weeks after completing radiation therapy. These samples will be used to measure
levels of neurotransmitters and hormone levels. These are substances which are released in
the body that may affect sleep and the immune system.
Length of Study:
You will remain on study for about 8 weeks after you complete radiation therapy.
This is an investigational study. Up to 20 patients will take part in this study. All will
be enrolled at M.D. Anderson.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |